Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Obertegger, G. Weskott, P. Surdakowski, K. Merfort, M. Glenschek-Sieberth (Wuppertal, Germany). Bactericidal activity of ciprofloxacin dry powder for inhalation (DPI) in a hollow fiber (HF) model. Eur Respir J 2014; 44: Suppl. 58, 4690

Member's Comments

No comment yet.

Related content which might interest you: Investigation of gram positive antibiotics as aerosol administration (cubicin, vancomycin, zyvoxid) Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Study of adherence to the use of inhaled sodium colistimethate through the I-neb® nebulization system Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Serological-diagnosis of chronic pulmonary aspergillosis (CPA) and aspergillus lateral-flow device (LFD) Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections Year: 2014 The impact of mixed etiology in community acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy Year: 2020 Inspiratory flow resistance of marketed dry powder inhalers (DPI) Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Effect of long term azithromycin on exacerbations in non CF bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Clinical cure rates in patients treated with azithromycin (AZ) for lower respiratory infections (LRTI) caused by AZ-susceptible (AZ-S) and AZ-resistant (AZ-R) organisms: Analysis of phase 3 clinical trials Source: International Congress 2014 – Respiratory symptoms in primary care populations Year: 2014 Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD Source: Annual Congress 2012 - Hot topics in respiratory infections Year: 2012 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Breakthrough invasive pulmonary aspergillosis (IPA) in patients receiving posaconazole prophylaxis (PPxis) Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI). Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019 LATE-BREAKING ABSTRACT: Pneumococcal serotypes causing community-acquired pneumonia (CAP) among hospitalized adults in Spain using a new urinary antigen detection (UAD) test. The CAPA study Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Antimicrobial susceptibility of pseudomonasaeruginosa in CF patients before and after regular treatment with inhaled tobramycin Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014